Augmentation of host immune responses to cancer: overcoming the barrier of tumor antigen-specific T-cell tolerance.
Levitsky
H I
HI
Johns Hopkins Oncology Center, Baltimore, Maryland 21231, USA.
D000818:Animals; D000938:Antigen-Presenting Cells / Q000502:physiology*; D016026:Bone Marrow Transplantation; D019013:CD40 Antigens / Q000378:metabolism; D019496:Cancer Vaccines; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D007108:Immune Tolerance; D007165:Immunosuppression Therapy; D007371:Interferon-gamma / Q000378:metabolism; D008168:Lung / Q000166:cytology; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology* / Q000502:physiology; D019139:Tumor Escape
D019013:CD40 Antigens; D019496:Cancer Vaccines; D007371:Interferon-gamma